Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218642 · ClinicalTrials.gov registry record · Phase 2
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
A Phase 2 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT05218642 is a Phase 2 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 123 participants.
The verdict
NCT05218642, a Phase 2 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
Interventions
- DRUG KX- 826 dosed at 2.5mg
- DRUG KX-826 dosed at 5mg
- DRUG Matching placebo to KX-826
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05218642
The ClinicalTrials.gov registry entry for NCT05218642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which KX- 826 dosed at 2.5mg is the first listed.
NCT05218642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05218642 about?
NCT05218642 is a clinical study titled "To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia". The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
What is the current status of trial NCT05218642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2022-01-31. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT05218642?
The interventions under investigation include: KX- 826 dosed at 2.5mg (DRUG), KX-826 dosed at 5mg (DRUG), Matching placebo to KX-826 (DRUG).
Who is sponsoring clinical trial NCT05218642?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.